Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06899958

Metabolism Enhancement by Laser Therapy

This is a single-center, open-label pilot study to determine the effect of large area fractional laser treatment (LAFLT) on adults' metabolic profile.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

MGH Clinical Unit for Research Trials & Outcomes in Skin

Boston, Massachusetts, 02114, United States

Location contact

Alicia Van Cott, NP

CONTACT

[email protected]

617-726-4454

About this study

The current research project aims to investigate the effects of large-area fractional laser treatment (LAFLT) on body weight, metabolism, and body composition. Prior research suggests that treating large skin areas with fractional laser therapy may stimulate metabolism and promote weight loss. The MIRIA laser, an FDA-approved fractional laser, is widely used for skin aging, acne scarring, and wrinkle reduction and will be used to evaluate these potential metabolic effects.

Subjects aged 18-60 with a BMI of 25-30 will undergo three fractional laser treatments on the abdomen and thighs over 36 weeks, with sessions every four weeks. The study includes six total visits, incorporating photography, non-invasive imaging, x-rays, blood draws, and two optional biopsies.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18- 60 years of age;
  • BMI between 25.0 and 30 kg/m2;
  • Subjects must be in good general health, based on answers provided during the screening visit;
  • Subject must be able and willing to provide written informed consent and comply with the requirements of the study protocol.
  • Females of childbearing potential must be willing and able to use a medically highly effective form of birth control during the entire study.

Exclusion criteria

  • Participation in another investigational drug or device clinical trial in the past 30 days;
  • Currently pregnant or pregnancy within the past 6 months or currently breastfeeding;
  • Have a history of drug or alcohol abuse in the past 3 years or have reported habitual alcohol intake greater than 2 standard drinks per day (e.g., 2 beers, 2 glasses of wine, or 2 mixed drinks);
  • Planning or currently participating in a weight loss program;
  • Plan to change daily diet or level of physical activity;
  • Intake of medication that may affect body weight such as GLP-1 receptor agonists, amitriptyline, bupropion, thyroid medications, etc.;
  • History of cancer which required lymph node biopsy or dissection;
  • Weight loss or gain of 10 kg or more in the past 6 months;
  • History of diabetes mellitus or cardiac disease;
  • Intake of hormone replacement therapy (HRT) in the last 6 months;
  • Infection, surgery, or history of trauma or laser treatment to the treatment area in the past 6 months;
  • Presence of any skin disease on the abdomen or thighs;
  • Have birthmarks, tattoos, scars, or any other disfiguration of the skin in the abdomen or thighs;
  • Presence of sunburn or tan in the abdomen or thighs;
  • Use of any topical application of retinoids in the past 6 weeks on the abdomen or thighs or intake of systemic retinoids in the past 6 months;
  • Use of any prescription topical medication, such as corticosteroids or hydroquinone on the abdomen or thighs in the past 6 weeks;
  • History of keloid formation or hypertrophic scarring;
  • History of bariatric surgery or other major weight-loss procedures;
  • History of abdominal liposuction, abdominoplasty or CoolSculpting;
  • Known allergy to lidocaine or other local anesthetics;
  • The investigator believes that the subject is an unsuitable candidate to participate in the study, receive laser treatment, or would be placed at risk by participating in the study.

Treatment and study plan

Fractional Laser

Device

Three fractional laser treatments to the abdomen and thighs at 4 week intervals.

Primary outcomes

  1. Percent Body Fat (%)

    Time frame: Week 1, 12, 24

    The percent body fat will be collected from the Dual energy x-ray absorptiometry scan (DEXA) and via the Bioelectrical Impedance Analysis (BIA).

  2. Body Mass Index (BMI) (kg/m²)

    Time frame: Week 0, 4, 8, 12, 24

    BMI will be calculated using the formula: weight (kg) / [height (m)]². Height will be measured at the baseline visit and body weight will be measured at each of the following visits.

  3. Waist circumference (cm)

    Time frame: Week 0, 4, 8, 12, 24

    These measurements will be taken at each of the following visits

  4. Hip circumference (cm)

    Time frame: Week 0, 4, 8, 12, 24

    These measurements will be taken at each of the following visits

  5. Arm circumference (cm)

    Time frame: Week 0, 4, 8, 12, 24

    These measurements will be taken at each of the following visits

  6. Total Lean Body Mass (kg)

    Time frame: Week 1, 12, 24

    The total lean body mass will be collected from the Dual energy x-ray absorptiometry scan (DEXA) and via the Bioelectrical Impedance Analysis (BIA).

Secondary outcomes

  1. Complete Blood Count (CBC)

    Time frame: Week 0, 4, 8, 12, 24

    Measurement of red blood cell count, white blood cell count, hemoglobin, hematocrit, and platelet count via a blood draw.

  2. Comprehensive Metabolic Panel (CMP)

    Time frame: Week 0, 4, 8, 12, 24

    Assessment of glucose, calcium, electrolyte and fluid balance (sodium, potassium, CO2, chloride), kidney function (BUN, creatinine), and liver function (albumin, total protein, ALP, ALT, AST, bilirubin) via a blood draw.

  3. Lipid Panel

    Time frame: Week 0, 4, 8, 12, 24

    Measurement of total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides via a blood draw.

  4. HbA1c

    Time frame: Week 0, 4, 8, 12, 24

    Measurement of hemoglobin A1c via a blood draw.

  5. C-Reactive Protein (CRP)

    Time frame: Week 0, 4, 8, 12, 24

    Measurement of CRP levels via a blood draw.

  6. Erythrocyte Sedimentation Rate (ESR)

    Time frame: Week 0, 4, 8, 12, 24

    Assessment of the rate at which red blood cells sediment via a blood draw.

  7. Histamine

    Time frame: Week 0, 4, 8, 12, 24

    Measurement of plasma histamine levels via a blood draw.

  8. Cortisol

    Time frame: Week 0, 4, 8, 12, 24

    Measurement of serum cortisol levels via a blood draw.

  9. Oxytocin

    Time frame: Week 0, 4, 8, 12, 24

    Measurement of serum oxytocin levels via a blood draw.

  10. Creatine Phosphokinase (CPK)

    Time frame: Week 0, 4, 8, 12, 24

    Measurement of serum CPK via a blood draw.

  11. Serum Interleukin-6 (IL-6)

    Time frame: Week 0, 4, 8, 12, 24

    Measurement of interleukin-6 (IL-6) via a blood draw.

  12. Serum Norepinephrine

    Time frame: Week 0, 4, 8, 12, 24

    Measurement of norepinephrine via a blood draw.

  13. Indirect Calorimetry

    Time frame: Week 0,12, 24

    This is a non-invasive procedure that measures how much energy the body uses.

  14. Skin Biopsy (Optional)

    Time frame: Week 1, 12

    2 optional biopsies will be take pre- and post-laser treatment to measure changes in collagen and skin thickness.

  15. Skin Elasticity

    Time frame: Week 0, 4, 8, 12, 24

    Ultrasound will be used to measure skin elasticity.

  16. Skin Thickness

    Time frame: Week 0, 4, 8, 12, 24

    Ultrasound will be used to measure skin thickness.

  17. Hydration Status (%)

    Time frame: Week 0, 12

    Estimation of total body water content as a percentage of body weight using the Bioelectrical impedance analysis (BIA).

  18. VAS Pain Score

    Time frame: Week 1, 4, 8

    The visual analog scale (VAS) pain score will be collected from the subject after each laser treatment. The VAS is a 10cm long scale with 0cm representing "no pain" and 10cm representing "worst possible pain".

  19. Total Body Bone Mineral Density (g/cm²)

    Time frame: Week 1, 12, 24

    The total body BMD will be collected from the Dual energy x-ray absorptiometry scan (DEXA).

Study contacts

Contact information is provided by the study sponsor or research team.

Alicia Van Cott, NP

CONTACT

[email protected]

617-726-4454

Maria Alora, MD

CONTACT

[email protected]

617-726-4454

Sponsors and collaborators

Lead sponsor

Massachusetts General Hospital

Other

Registry information

Acronym: MELT

Important dates

Study start
2027
Primary completion
2028
Study completion
2029
First posted
Mar 28, 2025
Registry last updated
Feb 11, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.